HTGM HTG MOLECULAR DIAGNOSTICS

HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) --  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

John Lubniewski, HTG CEO will be a participant in the panel discussion, “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!” at 9:50 am ET on September 28, 2022.

For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative.

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit .

HTG Investor Contact:        

                        

Ashley Robinson                        

LifeSci Advisors                         

Phone: (617) 430-7577                

Email:         



EN
26/09/2022

Underlying

HTGMHTG MOLECULAR DIAGNOSTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HTG MOLECULAR DIAGNOSTICS

 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG to Highlight the Advantages of its Drug Discovery Engine at the 20...

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach ...

May 18, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Highlights the Advantages of Its Drug Discovery Engine

HTG Highlights the Advantages of Its Drug Discovery Engine TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG’s objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostical...

May 16, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provi...

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG...

May 10, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Provides Update on Drug Discovery Partnering Initiative

HTG Provides Update on Drug Discovery Partnering Initiative TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG’s proprietary RNA profiling technologies, function...

April 25, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Announces Key First Quarter Milestone Achievements for Drug Discov...

HTG Announces Key First Quarter Milestone Achievements for Drug Discovery TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023. As reported in January 2023, HTG filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration ...

April 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch